I make these comments on behalf of OIC.
We thank the panellists for their informative presentations.
The report by UN Secretary General’s High Level Panel on Access to Medicines released in September 2016 has recommended that while building on the current discussions at the WHO, the UN Secretary-General should initiate a process for governments to negotiate global agreements on the coordination, financing and development of health technologies, including negotiations for a binding R&D convention that delinks costs of R&D from end prices to promote access to good health for all.
We have witnessed that the market-driven R&D system fails to deliver affordable medical products such as diagnostics, vaccines and medicines, in many areas including diseases that mainly affect poor populations -such as neglected tropical diseases; emerging epidemic/pandemic infectious diseases; and antibiotics.
It is important for developing countries without manufacturing capacity to explore all possible means to increase affordable access to medicines for their people, especially as the number of essential medicines under patent protection is expected to increase.
An important mean to ensure access to affordable medicines is through TRIPS flexibilities. Generic medicines are also manufactured and imported through the use of these flexibilities.
Can the panellists enlighten us about ways and means through which developing world can utilize TRIPs flexibilities to ensure availability of affordable generic medicines for their people?
I thank you.